HARA OYEDEJI: Open Payments
NPI 1497279053 · OWINGS MILLS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$269,482 in 341 payments from 15 companies in 2025. Trend: 2023 $178,863 · 2024 $263,988 · 2025 $269,482
Speaker / faculty: $150,621Consulting: $64,616Travel & lodging: $34,914Honoraria: $10,000Food & beverage: $9,331
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 116 | $115,801 |
| Alkermes, Inc. | 108 | $59,095 |
| Neurocrine BioSciences, Inc. | 52 | $49,555 |
| Teva Pharmaceuticals USA, Inc. | 15 | $18,974 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $13,236 |
| Luye Pharma (USA) Ltd. | 7 | $11,277 |
| Axsome Therapeutics, Inc. | 6 | $569 |
| ABBVIE INC. | 2 | $324 |
| Celgene Corporation | 2 | $180 |
| Lundbeck LLC | 1 | $137 |
Products named: COBENFY, INGREZZA, LYBALVI, ARISTADA, UZEDY, CAPLYTA, ERZOFRI EXTENDED-RELEASE, Auvelity.
Industry payments across MD — which companies pay providers there.
